AGC plans to install an additional twelve 2,000L single-use animal-cell bioreactors at their Seattle AGC Biologics site, as well as establish a new contract development and manufacturing facility for microbial manufacturing.
The post AGC Triples U.S. Biopharmaceutical Production Capacity appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Article: AGC Triples U.S. Biopharmaceutical Production Capacity